LATEST
外 Waitan Ludi Policy Terminal China industrial-policy monitor · updated 2026-11-10
view asAnalystMonitorPolicymakerBusinessLegal
← Documents · Graph

泉州市人民政府办公室关于印发泉州市促进医药产业健康发展实施方案的通知

Notice from the General Office of the Quanzhou Municipal People’s Government on the Issuance of the Implementation Plan for Promoting the Healthy Development of the Pharmaceutical Industry in Quanzhou
泉政办〔2017〕96号
Radar: Pharmaceuticals (rank 4 of 16)

Country-interest evidence · pilot

Trade inferences use UN Comtrade, with China as reporter. Country connections indicate potential trade relevance, not measured harm, firm-level exposure or legal applicability. Inward measures concern exporters to China; competition with Chinese exports in third markets is not assessed.

Inspect implementing jurisdictions and partner evidence · 39 relationships

Argentina: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 53,684,724

Australia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 558,351,570

Austria: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 296,702,687

Belgium: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 352,971,611

Bangladesh: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 1,123,110

Bulgaria: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 5,020,760

Brazil: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 21,178,865

Canada: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 153,787,445

Switzerland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 1,206,057,989

Cyprus: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 34,003,377

Germany: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 5,444,040,513

Denmark: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 527,810,507

Spain: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 392,328,554

Finland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 152,379,030

France: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 1,754,451,618

United Kingdom: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 1,034,970,483

Greece: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 45,964,395

Hong Kong, China: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 342,388,511

Croatia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 1,910,282

Hungary: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 56,854,844

Indonesia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 2,408,024

India: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 30,489,546

Ireland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 524,397,194

Israel: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 18,897,453

Italy: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 1,698,213,657

Japan: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 685,224,542

Korea, Rep.: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 144,864,741

Mexico: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 5,656,577

Netherlands: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 258,621,091

Norway: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 23,037,265

Poland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 18,014,442

Singapore: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 50,498,666

Slovenia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 12,818,533

Sweden: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 860,060,969

Thailand: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 7,727,338

Chinese Taipei: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 130,544,441

United States: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 2,971,377,450

South Africa: Trade-based inference; exporters to China; summed product trade > USD 1m; 2016 trade; broad sector headings; computed, not analyst-reviewed · intervention 54202 · recorded trade USD 118,044,013

Implementing jurisdiction: China · intervention 54202

Assessment states
  • Trade-based partners recorded

Measures

Tax relief
Prefectural · origin: Chinese firms or production in China · locality: Local firms · CPC 352 · Keyword screen (unreviewed)
Implemented by China (subnational) · affects 38 partners (inferred from trade data, 2016 trade): Germany, United States, France, Italy, Switzerland, United Kingdom …
继续落实省、市促进医药产业健康发展的各项优惠政策，加大高新技术医药企业的扶持力度，对经认定为高新技术企业的医药企业减按15%的税率征收企业所得税。
Tells lower levels to act; not itself a measure in force. Supports production in a place, so favours that place by rule.

Full text

各县（市、区）人民政府，泉州开发区、泉州台商投资区管委会，市人民政府各部门、各直属机构，各大企业，各高等院校： 《泉州市促进医药产业健康发展实施方案》已经市政府同意，现印发给你们，请结合实际，认真组织实施。 泉州市促进医药产业健康发展实施方案 为贯彻落实《福建省人民政府办公厅关于促进医药产业健康发展实施方案的通知》（闽政办〔2017〕22号）和《泉州市生物与新医药产业转型升级路线图》（泉政办〔2016〕38号）精神，推动“十三五”期间我市医药产业转型升级，促进医药产业健康发展，制定本实施方案。 一、总体要求 牢固树立和落实五大发展理念，坚持政府引导与市场推动相结合、自主创新与引进吸收相结合、重点突破与集聚发展相结合，通过优化政策环境、强化要素支撑、调整产业结构，实现医药产业整体素质明显提升，创新能力显著增强，产品质量全面提高，产业规模不断壮大，产业组织结构进一步优化。 二、主要目标 （一）规模进一步扩大。生物医药产业自2017年起，力争年均增长12%，到2020年，产值达到66亿元，培育形成10家销售收入达1亿元以上的骨干企业；医药流通业主营业务收入达到50亿元，年均增长12%。 （二）创新能力明显增强。建立以企业为主体、市场为导向、产学研相结合的产业创新体系。在规定期限内，完成仿制药质量和疗效一致性评价，提升药品质量水平。 三、主要任务 （一）增强产业创新能力。加强医药创新体系建设，发挥政府引导作用，加大财政科技投入，强化企业在技术创新体系中主体作用。推动政产学研医相结合，加强与境内外高校、科研院所、大企业合作，建设中药制剂关键技术研发平台、新型中药质量控制技术和质量标准体系，针对泉州现有名优中药制剂进行更新换代。加快建设海洋生物技术中试基地、海洋生物制品共性技术研发平台和海洋生物制品成果转化平台。进一步完善永春生物医药产业园、石狮海洋生物产业科技园、泉州开发区医药产业园服务平台功能，创新医药研发模式。鼓励来泉创办或合办医药重大研发机构，支持创建医药类国家、省、市重点实验室、工程实验室、企业（工程、行业）技术中心等。符合条件的科技创新平台、新型科研机构优先推荐享受省、市扶持政策。 责任单位：市科技局、财政局、发改委、经信委、卫计委、海洋渔业局、食品药品监管局、教育局，各县（市、区）人民政府，泉州开发区、泉州台商投资区管委会 （二）引导新产品研发。鼓励企业、科研机构开展中药及天然药物、海洋医药、生物制品研发与产业化，对符合条件的列入年度科技计划项目，给予资金资助。突出资源优势，扶持龙头企业，加强品牌建设，发挥示范带动作用，建立“企业+市场+药农+基地”现代化种植经营模式，推进药用植物生产产业化经营。引进或创建中药颗粒饮片、中药调料、汤包、药膳、药饮等系列药食同源产品。对疗效可靠、市场前景广阔的复方中成药进行二次开发。重点发展氨基葡萄糖、甲壳素、壳聚糖、胶原蛋白多肽、药用琼脂及地方中药熊胆粉等的产品制剂研发。开发临床体外诊断产品，细胞治疗产品，缓释、靶向制剂产品。鼓励开发3D打印医疗模型，将计算机影像数据信息形成实体结构，用于医学教学和手术模拟的医学道具、模型、用品等。针对需求量大、应用面广的体外诊断试剂等医疗器械，提高体外诊断试剂产品科技含量，推动由生产二类医疗器械向生产三类医疗器械迈进，积极引进1家科技含量高生产静脉留置针等的三类医疗器械台资企业在我市落户。 责任单位：市科技局、发改委、经信委、农业局、海洋渔业局、卫计委、食品药品监管局，各县（市、区）人民政府，泉州开发区、泉州台商投资区管委会 （三）推动中药现代化。加快名优中成药的剂型改造和二次创新、名医名方产业化开发，研制一批疗效确切、安全性高、有效成分明确、作用机理清晰的中药产品。鼓励中医药研究机构和医疗机构加强民间医药研发，鼓励将应用多年、疗效确切的医疗机构中药制剂开发成中成药。实施优质中药材生产，加强野生中药材资源保护，挖掘和继承道地中药材生产和产地加工技术，建立道地中药材种植养殖和产地加工标准化技术规范，提高和完善地方中药材标准和中药饮片炮制规范。探索建立覆盖主要中药材品种的全过程追溯体系。 责任单位：市科技局、经信委、发改委、卫计委、农业局、林业局、商务局、食品药品监管局、质监局，各县（市、区）人民政府，泉州开发区、泉州台商投资区管委会 （四）提升药品质量水平。全面实施并严格执行新版药品生产质量管理规范（GMP）和药品经营质量管理规范（GSP），健全药品安全追溯体系。严格遵守环保法律法规，注重配套设施建设，积极实施绿色酶法生产等技术改造。推进药品生产过程智能化，提升质量控制技术，完善质量标准体系；支持和加快仿制药质量和疗效一致性评价工作，对医药企业药品通过仿制药质量和疗效一致性评价的品种，按照《福建省人民政府办公厅关于推进仿制药质量和疗效一致性评价的实施意见》（闽政办〔2016〕181号）精神，积极向省医保办推荐纳入我省医保目录，享受与专利过期的原研药同一质量层次待遇，在药品联合采购和医保支付方面予以支持，同时鼓励我市医疗机构优先采购供临床选用。引导药品生产企业将闲置药品批文作为药品上市许可持有人申请注册，依申请委托生产。 责任单位：市食品药品监管局、卫计委、经信委、科技局、环保局、质监局、医保局、财政局，各县（市、区）人民政府，泉州开发区、泉州台商投资区管委会 （五）强化商业模式创新。按照省药品联合限价阳光采购规则，切实加强“两票制”落实情况的监督检查。强化医保结算，及时同药品流通企业结清货款，引导有实力的药品流通企业向社区和村镇延伸销售与配送网络。落实《泉州市人民政府办公室关于贯彻落实省政府办公厅“互联网+流通”行动计划实施方案的通知》（泉政办〔2016〕189号）精神，发展智慧物流配送体系，借助互联互通智慧化物流信息服务平台，提高药品流通效率。加强医药储备体系建设，确保储备药品及时轮换。 责任单位：市医保局、食品药品监管局、财政局、卫计委、商务局，各县（市、区）人民政府，泉州开发区、泉州台商投资区管委会 （六）优化产业布局。结合各县（市、区）区域优势，加强产业集聚区基础设施、服务平台和人力资源条件建设，把永春县、泉州开发区打造成为医药产业相对集中区域。永春县发挥药用动植物资源优势，重点发展中药种植与养殖、天然活性成分利用、药物制剂等，加快建设永春生物医药产业园；泉州开发区发挥药企集中和区位优势，重点发展传统中药制剂、化学药制剂、生物制品等，培育精准医学与健康服务、医疗器材等产业；泉州台商投资区依托建设中的泉州国家农业科技园区，发挥对台优势，加强与台湾地区生物医药科技产业合作，围绕生物农药、生物制药、医疗器械、医疗保健、体外检验试剂的研发、生产等领域，积极引进台湾乃至全球的企业来泉发展。鼓励泉港区、石狮市、晋江市、惠安县等地发挥沿海资源优势，重点发展海洋医药、生物制品等。 责任单位：市发改委、经信委、海洋渔业局、科技局，各县（市、区）人民政府，泉州开发区、泉州台商投资区管委会 四、保障措施 （一）落实优惠政策。继续落实省、市促进医药产业健康发展的各项优惠政策，加大高新技术医药企业的扶持力度，对经认定为高新技术企业的医药企业减按15%的税率征收企业所得税。对符合规划、确定优先发展且用地集约的医药工业企业项目用地，在年度用地计划指标中优先安排，落实用地出让底价和加层改造费用优惠政策。 责任单位：各县（市、区）人民政府，泉州开发区、泉州台商投资区管委会，市国税局、地税局，市经信委、食品药品监管局、国土资源局、财政局 （二）拓宽企业融资渠道。引导金融机构创新适合医药企业特点的金融产品与服务方式，加大对医药产业的信贷投入。积极运用“投资+贷款”模式支持初创期医药企业发展，推广知识产权、股权质押等无形资产质押融资模式，为初创期的企业提供资金支持。积极支持符合条件的医药企业发行短期融资券、超短期融资券、中期票据等银行间市场企业债券直接融资。鼓励银行业机构加强金融服务创新，争取试点投资收益抵补信贷风险，为科创企业提供持续资金支持，丰富科创型中小企业融资方式。 责任单位：市金融工作局、科技局，泉州银监分局、人民银行泉州市中心支行，各县（市、区）人民政府，泉州开发区、泉州台商投资区管委会 （三）营造良好市场环境。实施医疗、医保、医药联动改革，健全药品价格监测体系，推动价格信息公开。建立医保基金收支情况监控体系，根据医保基金承受能力，及时调整医保支付政策。大力发展商业健康保险，满足社会多样化健康保障和医药产品需求。推进医药企业诚信体系建设，改善市场诚信环境。加强征信宣传，依托“3·15国际消费者权益日”“6.14信用记录关爱日”等重要时间节点，对医药企业开展诚信宣传，营造“守信激励、失信惩戒”的良好社会氛围。 责任单位：市医改办、医保局、卫计委、财政局、物价局、工商局、食品药品监管局，市保险行业协会，各县（市、区）人民政府，泉州开发区、泉州台商投资区管委会 （四）强化人才支撑。根据《中共泉州市委泉州市人民政府关于实施人才“港湾计划”的若干意见》（泉委发〔2017〕6号）等文件精神，支持医药企业聘请急需专业人才，在资金补助、住房优惠、子女入学等方面给予优先扶持。实施“领军人才+创新团队+创新项目”的精准引才计划，每年遴选支持一批掌握核心技术、创新能力强、对医药产业创新发展发挥重要作用的人才团队。积极发动医药企业聘请工科类青年专业人才，发放企业聘用补助，按照《福建省工科类青年专业人才支持暂行办法》（闽委人才〔2016〕4号）规定发放补助。 责任单位：市人社局、科技局、财政局、住建局、教育局，市国税局、地税局，各县（市、区）人民政府，泉州开发区、泉州台商投资区管委会 各县（市、区）人民政府，泉州开发区、泉州台商投资区管委会及市直有关部门要充分认识促进医药产业健康发展的重要意义，加强组织领导，健全工作机制，各司其职，密切配合，形成工作合力，确保各项任务落到实处。